Abstract
Introduction: In the context of obesity and its comorbidities, more than 2.2 billion people are overweight or obese worldwide. By 2030, it is estimated that more than 60% of the world's population will be overweight or obese. Brazil has approximately 20 million obese people. In this context, and as a measure to mitigate this pathological scenario, nutrology combined with the use of the intragastric balloon (IGB) is an important pillar for obesity treatment. Also noteworthy is the 1-year adjustable balloon option, the Spatz3®, which offers the advantage of longer treatment with the possibility of adjustments to increase weight loss. Objective: the present study analyzed, through a systematic review, the main information and results of the use of the Spatz3® intragastric balloon, highlighting the volume adjustments up and down. Methods: The model followed for the systematic review was PRISMA. Databases such as Scopus, Embase, Cochrane, Scielo, Lilacs, Google Scholar, PubMed were used. A total of 136 clinical studies were submitted to the eligibility analysis and, after that, 20 studies were selected to compose the present study. The Risk of Bias was analyzed according to the Cochrane Instrument model. Main findings and Conclusion: Studies have shown that the treatment of obesity and super obesity with Spatz3® is a safe and effective procedure for weight reduction, without mortality, but with greater morbidity compared to traditional BIGs. Studies have also shown that adjusting the Spatz3® volume upwards allowed the balloon to remain in place for a longer time. However, the effectiveness of the upward adjustment still requires further confirmation. However, it is necessary for the professional to be well trained for the implantation of the intragastric balloon, as well as to know in depth the possible complications in an attempt to control the variables and reduce the chances of these occurrences. Although it may present risks of perforations and/or obstructions, the intragastric balloon represents an important alternative for superobese patients with high surgical risk for gastroplasty.